EGFR WT/T790M-IN-4 

EGFR WT/T790M-IN-4 is an anticancer agent. EGFR WT/T790M-IN-4 acts as an inhibitor of EGFR^WT and EGFR^T790M , with an IC₅₀ of 0.133 μM and 0.043 μM, respectively. EGFR WT/T790M-IN-4 also inhibits PI3K and mTOR kinases, with IC₅₀ values of 0.22 μM and 0.35 μM, respectively. EGFR WT/T790M-IN-4 induces cell cycle arrest and apoptosis in cancer cells, and inhibits cancer cell proliferation. EGFR WT/T790M-IN-4 can be used in research related to prostate cancer, colon cancer and breast cancer^[1].

EGFR WT/T790M-IN-4 (Compound 5d) (48 h) exhibits cytotoxic activity against PC-3, Caco-2 and MDA-231 cancer cell lines, with corresponding IC₅₀ values of 9.46 μM, 7.45 μM and 5.92 μM^[1].
EGFR WT/T790M-IN-4 (5.92 μM; 24 h) induces G1/S cell cycle arrest and apoptosis in MDA-231 breast cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

543.01

C₃₀H₂₇ClN₄O₄

O=C1N(CC(N/N=C(C)/C2=CC=CC=C2O)=O)N=C(/C=C/C3=CC=C(OC)C=C3)C=C1CC4=CC=C(Cl)C=C4

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ewieda SY, et al. Discovery of novel pyridazinone derivatives as EGFR^WT/ EGFR^T790M kinase inhibitors; design, synthesis, antitumor evaluation, and molecular dynamic simulations. Bioorg Chem. 2026;170:109486.  [Content Brief]